Source: Eur Respir J 2002; 19: 756-764
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Parry S.D., Barbatzas C., Peel E.T., Barton J.R.. Sulphasalazine and lung toxicity. Eur Respir J 2002; 19: 756-764

Member's Comments

No comment yet.

Related content which might interest you: Low-dose amiodarone therapy may be responsible of serious adverse pulmonary effects in patients without pre-existing lung disease Source: Eur Respir J 2004; 24: Suppl. 48, 280s Year: 2004 Acute lung injury as a possible adverse drug reaction related to gefitinib Source: Eur Respir J 2002 Jan 01;22(1):179-181 Year: 2003 Effectiveness and safety of leflunomide for pulmonary and extrapulmonary sarcoidosis Source: Eur Respir J 2011; 38: 1145-1150 Year: 2011 Drug-induced infiltrative lung disease Source: Eur Respir J 2001; 18: 93S-100S Year: 2001 Dose dependent increased mortality risk in COPD patients treated with oral glucocorticoids Source: Eur Respir J 2001; 17: 337-342 Year: 2001 Tiotropium as a first maintenance drug in COPD: secondary analysis of the UPLIFT(R) trial Source: Eur Respir J 2010; 36: 65-73 Year: 2010 Neomacrolides in airway disease Source: Annual Congress 2005 - New developments in infectious disease Year: 2005 Adverse pulmonary vascular effects of high dose tricyclic antidepressants: acute and chronic animal studies Source: Eur Respir J 2002; 20: 344-352 Year: 2002 Pulmonary toxicity with mefloquine Source: Eur Respir J 2001; 18: 890-892 Year: 2001 Where current pharmacological therapies fall short in COPD: symptom control is not enough Source: Eur Respir Rev 2007; 16: 98-104 Year: 2007 Drug-induced lung disease Source: Respipedia Article Year: 2017 Pharmacological characterisation of indacaterol (QAB149), a novel once-daily inhaled β2-agonist, on small airways in human and rat lung slices Source: Annual Congress 2006 - Novel treatments for asthma Year: 2006 Corticosteroid sensitivity in patients with chronic obstructive pulmonary disease is restored by theophylline Source: Annual Congress 2005 - Therapeutic options for COPD: present and future Year: 2005 Short- and long-term response to corticosteroid therapy in chronic beryllium disease Source: Eur Respir J 2008; 32: 687-693 Year: 2008 Immunosuppressive therapy after human lung transplantation Source: Eur Respir J 2004; 23: 159-171 Year: 2004 A comparison of the effects of lung function between low dose theophylline and oral β2-agonist in patients with chronic obstructive pulmonary disease Source: Eur Respir J 2006; 28: Suppl. 50, 215s Year: 2006 Side-effects of antituberculosis drug treatment in patients with chronic renal failure Source: Eur Respir J 2002; 20: 440-443 Year: 2002 Inhaled corticosteroids and survival in chronic obstructive pulmonary disease: does the dose matter? Source: Eur Respir J 2003; 21: 260-266 Year: 2003 Efficacy of switching from cyclosporine A to tacrolimus in patients with refractory CTD-ILD Source: International Congress 2016 – Connective tissue disorders Year: 2016 Single therapeutic and supratherapeutic doses of indacaterol have little effect on systemic safety variables in patients with chronic obstructive pulmonary disease (COPD) Source: Eur Respir J 2007; 30: Suppl. 51, 357s Year: 2007